Chordia Therapeutics Cash Flow Statement

Financials in millions JPY. Fiscal year is September - August.

Millions JPY. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Feb '26 Feb 28, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Net Income	-1,443	-1,786	-1,827	223.34
Depreciation & Amortization	1.48	2.7	4.09	6.04
Asset Writedown & Restructuring Costs	13.78	13.78	-	-
Other Operating Activities	17.52	128.24	-224.68	229.54
Change in Other Net Operating Assets	-199.51	-195.77	110.46	84.81
Operating Cash Flow	-1,334	-1,837	-1,937	543.73
Capital Expenditures	-4.66	-5.33	-0.54	-0.35
Sale (Purchase) of Intangibles	-	-	-	-0.38
Other Investing Activities	0.05	-	-10.42	1.07
Investing Cash Flow	-4.61	-5.33	-10.96	0.35
Issuance of Common Stock	509.89	61.58	1,479	-
Financing Cash Flow	509.89	61.58	1,479	-
Miscellaneous Cash Flow Adjustments	0	-0	-0	0
Net Cash Flow	-828.31	-1,781	-469.41	544.08
Free Cash Flow	-1,338	-1,842	-1,938	543.38
Free Cash Flow Margin	-	-	-	21.73%
Free Cash Flow Per Share	-19.14	-26.85	-32.99	9.63
Cash Income Tax Paid	2.42	2.42	2.42	2.42
Levered Free Cash Flow	-822.72	-1,192	-1,243	-
Unlevered Free Cash Flow	-822.72	-1,192	-1,243	-
Change in Working Capital	76.86	-195.77	110.46	84.81

Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.